Deadly sweet.

No abstract available

CommentOn

Eur J Prev Cardiol. 2025 Apr 2;32(5):404-414. doi: 10.1093/eurjpc/zwae288.

COI Statement

Conflict of interest: T.A.L. has consulting agreements with Novo Nordisk, Structure Therapeutics, and Prolynx. T.A.L. has or had collaborations with Novo Nordisk, Boehringer Ingelheim, Zealand Pharma, Aventis, IBM and Prolynx. None of these had an impact on this article. E.O. none.

Article info

Journal issue:

Volume: 32
Issue: 5

Doi:

10.1093/eurjpc/zwae387

More resources:

Atypon

Full Text Sources

Paid

Ovid Technologies, Inc.

Full Text Sources

Paid

Silverchair Information Systems

Full Text Sources

Paid